日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

对不适合接受强化化疗的急性髓系白血病患者进行低剂量阿糖胞苷和维奈托克治疗的风险分层

Wei, Andrew H; Panayiotidis, Panayiotis; Montesinos, Pau; Laribi, Kamel; Ivanov, Vladimir; Kim, Inho; Novak, Jan; Champion, Rebecca; Fiedler, Walter; Pagoni, Maria; Bergeron, Julie; Ting, Stephen B; Hou, Jing-Zhou; Yamauchi, Takahiro; Wang, Jianxiang; Strickland, Stephen A; Savona, Michael R; Lin, Tara L; Enjeti, Anoop; Tiong, Ing Soo; Lee, Sangmin; Roboz, Gail J; Popovic, Relja; Jiang, Qi; Liu, Zihuan; Sun, Yan; Mendes, Wellington; Chyla, Brenda; DiNardo, Courtney D

Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

Magrolimab联合阿扎胞苷与医生选择方案治疗未经治疗的TP53突变型急性髓系白血病:ENHANCE-2研究

Zeidner, Joshua F; Sallman, David A; Récher, Christian; Daver, Naval G; Leung, Anskar Y H; Hiwase, Devendra K; Subklewe, Marion; Pabst, Thomas; Montesinos, Pau; Larson, Richard A; Wilde, Lindsay; Enjeti, Anoop K; Kawashima, Ichiro; Papayannidis, Cristina; O'Nions, Jenny; Johnson, Lisa; Dong, Mei; Huang, Julie; Bagheri, Taravat; Hacohen Kleiman, Gal; Lee, Calvin; Vyas, Paresh

Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCs.

MDS 对阿扎胞苷的临床反应与 HSPC 中独特的 DNA 甲基化变化有关

Thoms Julie A I, Yan Feng, Hampton Henry R, Davidson Sarah, Joshi Swapna, Saw Jesslyn, Sarowar Chowdhury H, Lim Xin Ying, Nunez Andrea C, Kakadia Purvi M, Bhuyan Golam Sarower, Zou Xiaoheng, Nguyen Mary, Ghodousi Elaheh S, Koch Forrest C, Vafaee Fatemeh, Thompson I Richard, Karimi Mohammad M, Pickford Russell, Raftery Mark J, Hough Sally, Buckland Griselda, Bailey Michelle, Ghodke Yuvaraj, Absar Noorul, Vaughan Lachlin, Pasalic Leonardo, Fong Chun Y, Kenealy Melita, Hiwase Devendra K, Stoddart Rohanna I, Mohammed Soma, Lee Linda, Passam Freda H, Larsen Stephen R, Spring Kevin J, Skarratt Kristen K, Rebeiro Patricia, Presgrave Peter, Stevenson William S, Ling Silvia, Tiley Campbell, Fuller Stephen J, Roncolato Fernando, Enjeti Anoop K, Hoenemann Dirk, Lemech Charlotte, Jolly Christopher J, Bohlander Stefan K, Curtis David J, Wong Jason W H, Unnikrishnan Ashwin, Hertzberg Mark, Olivier Jake, Polizzotto Mark N, Pimanda John E

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

真实世界中患者的治疗结果与关键性 AML 试验中研究人群的治疗结果有多大可比性?

Tiong, Ing Soo; Wall, Meaghan; Bajel, Ashish; Kalro, Akash; Fleming, Shaun; Roberts, Andrew W; Thiagarajah, Nisha; Chua, Chong Chyn; Latimer, Maya; Yeung, David; Marlton, Paula; Johnston, Amanda; Enjeti, Anoop; Fong, Chun Yew; Cull, Gavin; Larsen, Stephen; Kennedy, Glen; Schwarer, Anthony; Kipp, David; Ramanathan, Sundra; Verner, Emma; Tiley, Campbell; Morris, Edward; Hahn, Uwe; Moore, John; Taper, John; Purtill, Duncan; Warburton, Pauline; Stevenson, William; Murphy, Nicholas; Tan, Peter; Beligaswatte, Ashanka; Mutsando, Howard; Hertzberg, Mark; Shortt, Jake; Szabo, Ferenc; Dunne, Karin; Wei, Andrew H

Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study

伊布替尼联合利妥昔单抗和mini-CHOP方案治疗老年新诊断弥漫性大B细胞淋巴瘤患者:一项2期ALLG研究

Verner, Emma; Johnston, Amanda; Pati, Nalini; Hawkes, Eliza A; Lee, Hui-Peng; Cochrane, Tara; Cheah, Chan Yoon; Filshie, Robin; Purtill, Duncan; Sia, Hanlon; Enjeti, Anoop K; Brown, Christina; Murphy, Nicholas; Curnow, Jennifer; Lee, Kenneth; Gandhi, Maher K; Walia, Mannu; Butcher, Belinda E; Trotman, Judith

Real-world study of the use of azacitidine in myelodysplasia in Australia

澳大利亚一项关于阿扎胞苷在骨髓增生异常综合征治疗中应用的真实世界研究

Enjeti, Anoop; Ashraf, Asma; Caillet, Vincent; Alam, Arif; Silar, Jonathan; Keer, Harold; Castaldi, Francesco; Paine, Taleisha

Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients

为临床医生、护理人员和患者制定骨髓增生异常综合征治疗偏好问卷

Morlock, Robert; Fong, Chun; Castaldi, Francesco; Paine, Taliesha; Collett, Donna; Enjeti, Anoop

Certainty in uncertainty: Determining the rate and reasons for reclassification of variants of uncertain significance in haematological malignancies

不确定性中的确定性:确定血液系统恶性肿瘤中意义未明变异的重新分类率和原因

Enjeti, Anoop K; Walker, Natasha; Fahey, Oliver; Johnston, Elizabeth; Legge-Wilkinson, Hannah; Ramsurrun, Nateika; Sillar, Jonathan; Lincz, Lisa F; Ziolkowski, Andrew; Mossman, David

High Expression of ENO1 and Low Levels of Circulating Anti-ENO1 Autoantibodies in Patients with Myelodysplastic Neoplasms and Acute Myeloid Leukaemia

骨髓增生异常肿瘤和急性髓系白血病患者中 ENO1 高表达和循环抗 ENO1 自身抗体水平低

Lisa F Lincz, Danielle Z Theron, Daniel L Barry, Fiona E Scorgie, Jonathan Sillar, Opelo Sefhore, Anoop K Enjeti, Kathryn A Skelding

Impact of the gut-lung axis on tuberculosis susceptibility and progression

肠-肺轴对结核病易感性和进展的影响

Enjeti, Aditya; Sathkumara, Harindra Darshana; Kupz, Andreas